Author

Xinfa Bai

Observed name: Bai, Xinfa

Institution: Luye Pharma (China)

Observed institutions: Yantai University, Luye Pharma (China)

OpenAlex ID: A5040860217

Small Molecules as SIRT Modulators

2016 · Xinfa Bai, Lei Yao, et al. · Mini-Reviews in Medicinal Chemistry · 92

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer

2022 · Jiahao Qiu, Xinfa Bai, et al. · Frontiers in Pharmacology · 15

Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of PLK1

2023 · Jing Lu, Hui Lei, et al. · Bioorganic Chemistry · 5

Synthesis and antitumor activities of 3-substituted-analine derivatives: structure modifications of Tuv part of tubulysins

2018 · Mingsha Shao, Xinfa Bai, et al. · Chemistry Central Journal · 3

A concise synthesis of Fingolimod: an orally available drug for treating multiple sclerosis

2015 · Ning Yan, Kai Chen, et al. · Chemistry Central Journal · 3

The Design, Synthesis and Preliminary Pharmacokinetic Evaluation of d3-Poziotinib Hydrochloride

2019 · Shuchao Ma, Linan Wang, et al. · Biological and Pharmaceutical Bulletin · 1

Synthesis and Anti-tumor Activity of Tubulysins Analogues†

2017 · Xinfa Bai, Xuan Ma, et al. · 1

Discovery of Novel, Potent Polo-Like Kinase 1 (PLK1) Inhibitors for the Treatment of Colorectal Cancer

2023 · Jing Lu, Hui Lei, et al. · SSRN Electronic Journal

9-Cyclopropylmethoxy-Dihydrotetrabenazine and Its Stereoisomers As Vesicular Monoamine Transporter-2 Inhibitors

2022 · Wenyan Wang, Shilan Lin, et al. · Future Medicinal Chemistry

Works count: 13

Citation count: 120

H-index: 3

I10-index: 2